Erratum: Golimumab, a new human anti-tumor necrosis factor α antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study

Joel Kremer; Christopher Ritchlin; Alan Mendelsohn; Daniel Baker; Lilianne Kim; Zhenhua Xu; John Han; Peter Taylor

doi:10.1002/art.27747

Erratum: Golimumab, a new human anti-tumor necrosis factor α antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study

Arthritis & Rheumatism ◽

10.1002/art.27747 ◽

2010 ◽

Vol 62 (10) ◽

pp. 3130-3130 ◽

Cited By ~ 2

Author(s):

Joel Kremer ◽

Christopher Ritchlin ◽

Alan Mendelsohn ◽

Daniel Baker ◽

Lilianne Kim ◽

...

Keyword(s):

Tumor Necrosis ◽

Tumor Necrosis Factor Α ◽

Active Rheumatoid Arthritis ◽

Phase Iii ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Factor Α ◽

Necrosis Factor

Download Full-text

Golimumab, a new human anti-tumor necrosis factor α antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study

Arthritis & Rheumatism ◽

10.1002/art.27348 ◽

2010 ◽

Vol 62 (4) ◽

pp. 917-928 ◽

Cited By ~ 76

Author(s):

Joel Kremer ◽

Christopher Ritchlin ◽

Alan Mendelsohn ◽

Daniel Baker ◽

Lilianne Kim ◽

...

Keyword(s):

Tumor Necrosis ◽

Tumor Necrosis Factor Α ◽

Active Rheumatoid Arthritis ◽

Phase Iii ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Factor Α ◽

Necrosis Factor

Download Full-text

Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor α inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study

Arthritis Research & Therapy ◽

10.1186/s13075-015-0516-6 ◽

2015 ◽

Vol 17 (1) ◽

Cited By ~ 28

Author(s):

Josef S Smolen ◽

Jonathan Kay ◽

Mittie Doyle ◽

Robert Landewé ◽

Eric L Matteson ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Tumor Necrosis Factor Α ◽

Active Rheumatoid Arthritis ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Factor Α ◽

Necrosis Factor

Download Full-text

Tumor necrosis factor-α blockade in recurrent and disabling chronic sciatica associated with post-operative peridural lumbar fibrosis: results of a double-blind, placebo randomized controlled study

Arthritis Research & Therapy ◽

10.1186/s13075-015-0838-4 ◽

2015 ◽

Vol 17 (1) ◽

Cited By ~ 3

Author(s):

Christelle Nguyen ◽

Clémence Palazzo ◽

Sophie Grabar ◽

Antoine Feydy ◽

Katherine Sanchez ◽

...

Keyword(s):

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Tumor Necrosis Factor Α ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Randomized Controlled ◽

Chronic Sciatica ◽

Factor Α ◽

Necrosis Factor

Download Full-text

A Randomized, Double-blind, Placebo-controlled Study of Tumor Necrosis Factor-α Blockade in Severe Persistent Asthma

American Journal of Respiratory and Critical Care Medicine ◽

10.1164/rccm.200809-1512oc ◽

2009 ◽

Vol 179 (7) ◽

pp. 549-558 ◽

Cited By ~ 317

Author(s):

Sally E. Wenzel ◽

Peter J. Barnes ◽

Eugene R. Bleecker ◽

Jean Bousquet ◽

William Busse ◽

...

Keyword(s):

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Tumor Necrosis Factor Α ◽

Persistent Asthma ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Severe Persistent Asthma ◽

Factor Α ◽

Necrosis Factor

Download Full-text

Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

Arthritis & Rheumatism ◽

10.1002/art.22025 ◽

2006 ◽

Vol 54 (9) ◽

pp. 2793-2806 ◽

Cited By ~ 1041

Author(s):

Stanley B. Cohen ◽

Paul Emery ◽

Maria W. Greenwald ◽

Maxime Dougados ◽

Richard A. Furie ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis ◽

Phase Iii ◽

Primary Efficacy ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Factor Therapy ◽

Necrosis Factor

Download Full-text

Faculty Opinions recommendation of Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.734268130.793576219 ◽

2020 ◽

Author(s):

Pedro Machado

Keyword(s):

Tumor Necrosis ◽

Axial Spondyloarthritis ◽

Controlled Trial ◽

Phase Iii ◽

Inadequate Response ◽

Tumor Necrosis Factor Inhibitors ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Necrosis Factor

Download Full-text

Ustekinumab in active psoriatic arthritis including patients previously treated with anti–tumor necrosis factor agents: Week 24 results from PSUMMIT 2, a phase III, multicenter, double-blind, placebo-controlled study

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2012.12.895 ◽

2013 ◽

Vol 68 (4) ◽

pp. AB217

Keyword(s):

Psoriatic Arthritis ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Phase Iii ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Previously Treated ◽

Necrosis Factor

Download Full-text

Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-α, in Patients With Moderate-to-Severe Heart Failure

Circulation ◽

10.1161/01.cir.0000077913.60364.d2 ◽

2003 ◽

Vol 107 (25) ◽

pp. 3133-3140 ◽

Cited By ~ 932

Author(s):

Eugene S. Chung ◽

Milton Packer ◽

Kim Hung Lo ◽

Adedigbo A. Fasanmade ◽

James T. Willerson

Keyword(s):

Heart Failure ◽

Monoclonal Antibody ◽

Tumor Necrosis ◽

Tumor Necrosis Factor Α ◽

Pilot Trial ◽

Severe Heart Failure ◽

Double Blind ◽

Double Blind Placebo ◽

Factor Α ◽

Necrosis Factor

Download Full-text

Faculty Opinions recommendation of Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718325315.793492809 ◽

2014 ◽

Author(s):

Ronald van Vollenhoven

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis ◽

Phase Iii ◽

Primary Efficacy ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Factor Therapy ◽

Necrosis Factor

Download Full-text

Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis

Arthritis & Rheumatism ◽

10.1002/art.24638 ◽

2009 ◽

Vol 60 (8) ◽

pp. 2272-2283 ◽

Cited By ~ 287

Author(s):

Paul Emery ◽

Roy M. Fleischmann ◽

Larry W. Moreland ◽

Elizabeth C. Hsia ◽

Ingrid Strusberg ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Active Rheumatoid Arthritis ◽

Phase Iii ◽

Controlled Study ◽

First Line ◽

Double Blind ◽

First Line Therapy ◽

Line Therapy ◽

Factor Α ◽

Necrosis Factor

Download Full-text